Reference:
Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Fang, Q. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207. https://doi.org/10.1016/j.phrs.2020.105207
Summary:
Since January 2020, Elsevier has provided a COVID-19 resource centre offering free access to research on the virus, enabling unrestricted reuse and analysis, including in repositories like PubMed Central. Furthermore, ivermectin, an antiparasitic drug, shows promising anticancer properties by inhibiting tumour cell proliferation through various mechanisms, including the modulation of signalling pathways like Akt/mTOR and Wnt. This review discusses the potential of ivermectin as a therapeutic agent across different cancers, highlighting its ability to induce programmed cell death and reverse drug resistance. Given its established safety profile from years of use in treating parasitic diseases, ivermectin represents a viable candidate for repurposing in cancer therapy.